Sep. 14 at 8:38 PM
$AMRN $NVS If only there was a company where strategic fit + quality clinical evidence included REDUCE-IT already delivering Phase 3 CV outcomes data with proven event reduction, EVAPORATE adding coronary plaque evidence, EPA/PCSK9 research overlapping directly with your LDL-lowering franchise (our current board sold you inclisarin/leqvio), Lp(a) work showing reduced Lp(a) oxidation, inflammation data supporting effects beyond triglyceride lowering, HF analyses showing lower heart failure risk (entresto lane) with higher achieved EPA, and the entire platform sitting across secondary prevention, residual risk, plaque, inflammation and lipid management, add LR-EtEPA as a potential protected 505(b)(2) lifecycle reset, plus existing European ecosystem overlap through GOLDEN, BioInnova, NHS, Spain and multiple European CV programs you guys already own and LATM commercialization left open without a partner for direct takeover that fits into your 5 to 10 billion acquisition thesis/goals...
